Crosslink Therapeutics files to raise $5.5M in equity offering

Crosslink Therapeutics Inc., a Boston-based biotechnology company, filed a Form D with the U.S. Securities and Exchange Commission indicating intent to raise $5.5 million in an equity financing round ^[1]. Such regulatory disclosures are standard procedure for companies conducting exempt securities offerings in the United States ^[1].

The regulatory filing indicates that the initial transaction closed on Oct. 8, 2026 ^[1]. The company, which was incorporated in 2021, has not disclosed external venture backers, syndicate participants, or specific operational plans for the capital ^[1].

Crosslink Therapeutics has kept the underlying therapeutic focus and pipeline milestones undisclosed in the notice of exempt offering ^[1]. Details regarding an overall target valuation or additional closings were also absent from the regulatory document ^[1].